Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XZP 3621

Drug Profile

XZP 3621

Alternative Names: XZP-3621

Latest Information Update: 04 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xuanzhu Biopharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Preclinical Cancer

Most Recent Events

  • 01 May 2023 Xuanzhu Biopharmaceutical plans a pharmacokinetics phase I trial (In healthy volunteers, In adults) in China (PO) in May 2023 (NCT05836805)
  • 19 Oct 2022 Xuanzhu Biopharmaceutical plans a phase I trial in healthy subjects in China (PO) (NCT05586568)
  • 05 Aug 2022 Xuanzhu Biopharmaceutical plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Recurrent) in China (PO) (NCT05482087)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top